EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Protective Role for Itaconate During Inhaled Allergen Challenge

Gesa J Albers iD, Patricia P Ogger, Christina Michalaki, Helen Stölting iD, Simone A Walker, Anna Caldwell, John M Halket, Kathryn Duvall, Atia Batool, Lisha Joshi, Helen O'Brien iD, Cormac McCarthy und 5 weitere

Allergy · 2026

DOI: 10.1111/all.70107 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, 2026. Verfasst von Gesa J Albers und 16 weiteren Autor:innen. Beteiligte Einrichtung: National Heart and Lung Institute, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Succinates, Asthma, Allergens. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Asthma and Lung UK, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Asthma is a chronic, heterogeneous disease characterised by airway remodelling, inflammation, and mucus production. Airway macrophages' functions are underpinned by changes in cellular metabolism. The TCA cycle‐derived metabolite itaconic acid (whose synthesis is mediated by aconitate decarboxylase) is a master regulator of macrophage function; however, its role during inhaled allergen challenge is not clear. The objective of this study was to define the role of itaconate during inhaled allergen challenge.

Methods

Sputum metabolite levels were measured in participants with mild allergic asthma undergoing allergen inhalation challenge, and in a second cohort, baseline levels in mild, moderate, and severe asthmatics. Airway inflammation, lung function, and bronchoalveolar lavage metabolite levels were assessed in wild‐type and aconitate decarboxylase‐deficient mice, or in mice treated with inhaled itaconate.

Results

Allergen inhalation in mild asthmatics led to a significant reduction in sputum itaconate. We found no difference in baseline sputum itaconate levels when comparing healthy controls to mild, moderate, or severe asthmatics. Continuous exposure to aeroallergen in wild type and aconitate decarboxylase‐deficient mice showed no change in disease phenotype after 48 h, 1, 3, or 5 weeks of allergen exposure. Treatment of house dust mite‐exposed mice with inhaled itaconate reduced airway inflammation.

Conclusion

Levels of itaconate are altered after allergen challenge in mild asthmatics and in murine models of disease. Itaconate deficiency did not alter house dust mite‐induced pathology at any of the timepoints tested; however, inhaled itaconate ameliorated inflammatory responses to inhaled allergen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SuccinatesAsthmaAllergensAnimalsHumansMiceFemaleMaleAdultMiddle AgedDisease Models, AnimalSputumAdministration, InhalationYoung Adult

Stichwörter der Autor:innen

airway inflammationallergen exposureasthmaitaconatemacrophage metabolism

Substanzen

Succinatesitaconic acidAllergens

Autor:innen und Institutionen

  • National Heart and Lung Institute, Imperial College London, London, UK.
  • Department of Nutritional Sciences, School of Life Course & Population Health Sciences, King's College London, London, UK.
  • Conway Institute and School of Medicine, University College Dublin, Dublin, Ireland.
  • Respiratory Medicine Unit, Nuffield Department of Medicine and National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
  • Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Sir Henry Wellcome Laboratories, and the NIHR Southampton Respiratory Biomedical Research Unit, Southampton University Hospital, Southam…
  • Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

ORCID-Profile: Gesa J Albers, Helen Stölting, Helen O'Brien, Timothy Hinks, Gail M Gauvreau, Adam J Byrne

Förderung

  • Asthma and Lung UK
  • Wellcome Trust

Zitieren

APA

Albers, G. J., Ogger, P. P., Michalaki, C., Stölting, H., Walker, S. A., Caldwell, A., Halket, J. M., Duvall, K., Batool, A., Joshi, L., O'Brien, H., McCarthy, C., Hinks, T., Gauvreau, G. M., O'Byrne, P. M., Lloyd, C. M., & Byrne, A. J. (2026). Protective Role for Itaconate During Inhaled Allergen Challenge. Allergy. https://doi.org/10.1111/all.70107

Vancouver

Albers GJ, Ogger PP, Michalaki C, Stölting H, Walker SA, Caldwell A, et al. Protective Role for Itaconate During Inhaled Allergen Challenge. Allergy. 2026. doi:10.1111/all.70107

BibTeX
@article{Albers2026,
  author = {Albers, Gesa J and Ogger, Patricia P and Michalaki, Christina and Stölting, Helen and Walker, Simone A and Caldwell, Anna and Halket, John M and Duvall, Kathryn and Batool, Atia and Joshi, Lisha and O'Brien, Helen and McCarthy, Cormac and Hinks, Timothy and Gauvreau, Gail M and O'Byrne, Paul M and Lloyd, Clare M and Byrne, Adam J},
  title = {Protective Role for Itaconate During Inhaled Allergen Challenge},
  journal = {Allergy},
  year = {2026},
  doi = {10.1111/all.70107}
}
Kostenlos starten →